27896234|t|Frequency and Associated Factors of Amphotericin B Nephrotoxicity in Hospitalized Patients in Hematology-Oncology Wards in the Southwest of Iran.
27896234|a|BACKGROUND: Nephrotoxicity is the most clinically significant adverse reaction of amphotericin B. Different aspects of amphotericin B (AmB) nephrotoxicity have not been studied well in our population. OBJECTIVES: The purpose of this study was to assess the frequency, time onset, and possible associated factors of AmB nephrotoxicity in hospitalized patients in hematology-oncology wards in the southwest of Iran. PATIENTS AND METHODS: A cross-sectional, observational study was performed over a period of 9 months at 2 hematology-oncology and 1 hematopoietic stem cell transplantation wards at Namazi Hospital. Patients aged 15 years or older with no documented history of acute kidney injury or chronic kidney disease who were scheduled to receive formulations of AmB intravenously for at least 1 week were included. The required demographic and clinical data of the patients were recorded. Urine urea, creatinine, sodium, potassium, and magnesium levels were measured at days 0, 3, 5, 7, 10, and 14 of the AmB treatment. AmB nephrotoxicity based on serum creatinine increase, renal potassium wasting, hypokalemia, and hypomagnesemia were determined. RESULTS: Among the 40 patients recruited for the study, 11 (27.5%) patients developed AmB nephrotoxicity with a mean +- standard deviation onset of 6.73 +- 2.36 days. In 5 patients, AmB nephrotoxicity resolved spontaneously without any intervention. According to the multivariate logistic regression model, none of the studied demographic, clinical, and paraclinical variables were significantly associated with AmB nephrotoxicity. The duration of hospitalization (P = 0.541) and the mortality rate (P = 0.723) were comparable between the patients with and without AmB nephrotoxicity. Hypokalemia and renal potassium wasting were identified in 45% and 27.5% of the patients during AmB treatment, respectively. CONCLUSIONS: Nearly one-third (27.5%) of our cohort developed nephrotoxicity within the first week of AmB treatment. Hypokalemia and renal potassium wasting were more notable, affecting about one-half and one-third of the AmB recipients, respectively.
27896234	36	50	Amphotericin B	Chemical	MESH:D000666
27896234	51	65	Nephrotoxicity	Disease	
27896234	82	90	Patients	Species	9606
27896234	158	172	Nephrotoxicity	Disease	
27896234	228	243	amphotericin B.	Chemical	MESH:D000666
27896234	265	279	amphotericin B	Chemical	MESH:D000666
27896234	281	284	AmB	Chemical	MESH:D000666
27896234	286	300	nephrotoxicity	Disease	
27896234	461	464	AmB	Chemical	MESH:D000666
27896234	465	479	nephrotoxicity	Disease	
27896234	496	504	patients	Species	9606
27896234	560	568	PATIENTS	Species	9606
27896234	758	766	Patients	Species	9606
27896234	820	839	acute kidney injury	Disease	MESH:D058186
27896234	843	865	chronic kidney disease	Disease	MESH:D051436
27896234	912	915	AmB	Chemical	MESH:D000666
27896234	1015	1023	patients	Species	9606
27896234	1045	1049	urea	Chemical	MESH:D014508
27896234	1051	1061	creatinine	Chemical	MESH:D003404
27896234	1063	1069	sodium	Chemical	MESH:D012964
27896234	1071	1080	potassium	Chemical	MESH:D011188
27896234	1086	1095	magnesium	Chemical	MESH:D008274
27896234	1155	1158	AmB	Chemical	MESH:D000666
27896234	1170	1173	AmB	Chemical	MESH:D000666
27896234	1174	1188	nephrotoxicity	Disease	
27896234	1204	1214	creatinine	Chemical	MESH:D003404
27896234	1225	1248	renal potassium wasting	Disease	MESH:D011191
27896234	1250	1261	hypokalemia	Disease	MESH:D007008
27896234	1267	1281	hypomagnesemia	Disease	OMIM:613882
27896234	1321	1329	patients	Species	9606
27896234	1366	1374	patients	Species	9606
27896234	1385	1388	AmB	Chemical	MESH:D000666
27896234	1389	1403	nephrotoxicity	Disease	
27896234	1471	1479	patients	Species	9606
27896234	1481	1484	AmB	Chemical	MESH:D000666
27896234	1485	1499	nephrotoxicity	Disease	
27896234	1711	1714	AmB	Chemical	MESH:D000666
27896234	1715	1729	nephrotoxicity	Disease	
27896234	1838	1846	patients	Species	9606
27896234	1864	1867	AmB	Chemical	MESH:D000666
27896234	1868	1882	nephrotoxicity	Disease	
27896234	1884	1895	Hypokalemia	Disease	MESH:D007008
27896234	1900	1923	renal potassium wasting	Disease	MESH:D011191
27896234	1964	1972	patients	Species	9606
27896234	1980	1983	AmB	Chemical	MESH:D000666
27896234	2071	2085	nephrotoxicity	Disease	
27896234	2111	2114	AmB	Chemical	MESH:D000666
27896234	2126	2137	Hypokalemia	Disease	MESH:D007008
27896234	2142	2165	renal potassium wasting	Disease	MESH:D011191
27896234	2231	2234	AmB	Chemical	MESH:D000666
27896234	Positive_Correlation	MESH:D000666	MESH:D007008
27896234	Positive_Correlation	MESH:D000666	OMIM:613882
27896234	Positive_Correlation	MESH:D000666	MESH:D011191

